TherapeuticsMD, Inc. , a women's healthcare company , announced today that it has initiated the SPRY Trial, a randomized, placebo-controlled phase 3 clinical trial designed to evaluate the safety and efficacy of TX 12-002-HR, its oral progesterone candidate for secondary amenorrhea, a condition treated to maintain fertility in young premenopausal ... (more)
http://ift.tt/1mBtEnG
http://ift.tt/1mBtEnG
No comments:
Post a Comment